# US 11,442,066 B2 · Method for identifying drug-discovery target protein for development of antibody drug, and method for producing antibody against target protein

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,442,066 B2
- Document ID: US11442066B2
- Status: Granted
- Kind: B2
- Application number: 16/486,723
- Filed: 2018-02-19
- Published: 2019-12-19
- Granted: 2022-09-13
- Earliest claimed: 2017-02-17
- Assignees: Mitsui Chemicals, Inc.; National Institutes of Biomedical Innovation, Health and Nutrition; Savid Therapeutics Inc.
- Applicants: Mitsui Chemicals, Inc.; National Institutes of Biomedical Innovation, Health and Nutrition; Savid Therapeutics Inc.
- Inventors: Tsuneji Suzuki; Yoshiyuki Totani; Kosuke Mano; Shinichi Banba; Haruhiko Kamada; Taisuke Nakayama; Hiroki Akiba; Kouhei Tsumoto; Tsuyoshi Inoue
- Web page: https://patentgrep.com/patent/US11442066B2

## CPC

- G01N 33/58: involving labelled substances (G01N33/53 takes precedence)
- C07D 207/40: 2,5-Pyrrolidine-diones
- C07D 233/20: with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07K 14/36: from Actinomyces; from Streptomyces (G)
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- C07K 2317/10: characterized by their source of isolation or production
- G01N 33/54353: {with ligand attached to the carrier via a chemical coupling agent (coatings G01N33/54393)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Finding a protein of a minute amount present on a cell membrane to provide a method for producing an antibody against the protein. Producing an antibody using a protein identified by an identification method including: a labeling step of using a labeling agent comprising at least one selected from bis-iminobiotin compounds and bis-biotin compounds to obtain cells having a labeled protein; a degradation step of preparing a degradation product for an immobilization treatment, the degradation product containing the labeled protein; an immobilization step of immobilizing the labeled protein contained in the degradation product for an immobilization treatment on a stationary phase via a streptavidin mutant; a cleavage step of releasing an analysis sample from the stationary phase on which the labeled protein is immobilized; and an analysis step of analyzing the analysis sample to identify the labeled protein.

## Claims

### Claim 1

A bis-iminobiotin compound selected from the group consisting of compounds shown in following Tables A3 to A10:
TABLE A3
1
2
3
4
5
6
TABLE A4
1
2
3
4
5
6
7
TABLE A5
1
2
3
4
5
TABLE A6
1
2
3
4
5
TABLE A7
1
2
3
4
5
TABLE A8
1
2
3
4
5
TABLE A9
1
2
3
4
5
6
TABLE A10
1
2
3
4
5
6
wherein X is NH, J is sulfur, L is NH, G-Y is selected from the groups shown in following Table G2, wherein E means a bond to a partial structure in each of the compounds shown in the Tables A3 to A10, and Y is an N-hydroxysuccinimide ester or an N-hydroxysulfosuccinimide ester:
TABLE G2
1
2
3
4
8
9
11

### Claim 2 (depends on 1)

A labeling compound for a protein, wherein
the labeling compound is at least one selected from the bis-iminobiotin compounds according to claim 1.

### Claim 3 (depends on 2)

The labeling compound for a protein according to claim 2, wherein labeling of the protein is performed for identification of the protein.